Feedback on FDA's Guidance for Patient Reported Outcome Measures
Author Information
Author(s): Bradley Clare
Primary Institution: Health Psychology Research, Royal Holloway, University of London
Hypothesis
The FDA guidelines on Patient Reported Outcome measures need improvements to better distinguish between health status and quality of life.
Conclusion
The author believes that while the FDA guidelines have encouraged good practices, they require significant revisions to accurately reflect the importance of quality of life in patient care.
Supporting Evidence
- The FDA's guidelines lack references, which diminishes their credibility.
- Quality of life and health status are distinct concepts that should not be conflated.
- Patients can provide valuable insights into their quality of life if given the right measures.
Takeaway
The FDA's guidelines on how to measure patient-reported outcomes need to be clearer so that doctors can better understand how patients feel about their health and quality of life.
Potential Biases
The FDA's definitions may lead to misinterpretations of health status and quality of life.
Limitations
The FDA's lack of references in their guidelines undermines their credibility.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website